Characteristics of the first opioid dispensation within 90 days’ post-discharge.

Characteristics of the first opioid dispensation within 90 days’ post-discharge.</p

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by number of cumulative and number of continuous days of use to define long term use.

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by number of cumulative and number of continuous days of use to define long term use.</p

The association between patient, medication and system-level characteristics and time to long term use within the one-year post-discharge.

The association between patient, medication and system-level characteristics and time to long term use within the one-year post-discharge.</p

Flowchart of patients’ history of opioid use prior to admission, during the hospitalization, at hospital discharge and 3 month’s post-discharge.

Flowchart of patients’ history of opioid use prior to admission, during the hospitalization, at hospital discharge and 3 month’s post-discharge.</p

S1 File -

(DOCX)</p

Characteristics of long term opioid users’ vs episodic opioid users based on cumulative opioid ≥60 days’ supply of opioids to define long-term use.

Characteristics of long term opioid users’ vs episodic opioid users based on cumulative opioid ≥60 days’ supply of opioids to define long-term use.</p

Surgery and Patient Rates, stratified by gender (per 10,000 population).

<p>Surgery and Patient Rates, stratified by gender (per 10,000 population).</p

Patient Surgery Rates, stratified by age (per 10,000 population).

<p>Patient Surgery Rates, stratified by age (per 10,000 population).</p

Characteristics of Carpal Tunnel Surgery Patients: All Surgeries between Jan 1 1993 and December 31 2009.

<p><b>Abbreviations:</b> N: Number; SD: Standard Deviation; NCS: Nerve Conduction Study; CTS: Carpal Tunnel Syndrome; OHIP: Ontario Health Insurance Plan.</p

Baseline Characteristics of Men Newly Prescribed Testosterone between April 1 2010 and March 31 2012.

<p>*Indicates a statistically significant difference (p-value<0.05) when comparing injectable to topical patient group.</p><p>**Indicates a statistically significant difference (p-value<0.05) when comparing oral to topical patient group.</p>‡<p>Cells suppressed due to small numbers to protect the privacy of patients.</p